Stereoselective analyses of selegiline metabolites: Possible urinary markers for selegiline therapy

Forensic Science International

Volumn 101, Issue 2, 1999, Pages 95-106

  Hasegawa, Masanori ^a,b   Matsubara, Kazuo ^c   Fukushima, Shoju ^a   Maseda, Chikatoshi ^b   Uezono, Takashi ^a   Kimura, Kojiro ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b 690 8510   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Amphetamine; Chiral urinalysis; Desmethylselegiline; Drug abuse; Metabolism; Methamphetamine; Selegiline

Indexed keywords

DRUG METABOLITE; METHAMPHETAMINE; SELEGILINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; DRUG METABOLISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEREOISOMERISM; TECHNIQUE; URINALYSIS;

EID: 0032949075     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0379-0738(99)00015-8     Document Type: Article

References (30)

1. Birkmayer W., Riederer P., Youdim M.B.H., Linauer W. The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B. Deprenil. J. Neural. Transm. 36:1975;303-326.
2. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levadopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Br. Med. J. 311:1995;1602-1607.
3. Olanow C.W., Godbold J.H., Koller W. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Patients taking selegiline may have received more levodopa than necessary. Br. Med. J. 312:1996;702-703.
4. Carrillo M.C., Kanai S., Nokubo M., Kitani K. (-) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48:1991;517-521.
5. + in vivo. Eur. J. Pharmacol. 243:1993;241-247.
6. Koutsilieri E., Chen T.S., Rausch W.D., Riederer P. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. Eur. J. Pharmacol. 306:1996;181-186.
7. Knollema S., Aukema W., Hom H., Korf J., Horst G.J.T. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke. 26:1995;1883-1887.
8. Semkova I., Wolz P., Schilling M., Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 315:1996;19-30.
9. Mytilineou C., Radcliffe P., Leonardi E.K., Werner P., Olanow C.W. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J. Neurochem. 68:1997;33-39.
10. Mytilineou C., Radcliffe P.M., Olanow C.W. L-(-)-Desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J. Neurochem. 68:1997;434-436.
11. Reynolds G.I., Elsworth J.D., Blau K., Sandler M., Lees A.J., Stern G.M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6:1978;542-544.
12. Heinonen E.F., Myllyhi V., Sotaniemi K., Lammintausta R., Salonen J.S., Anttila M., Savijärvi M., Kotila M., Rinne U.K. Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. 126:1989;93-99.
13. Maurer H.H., Kraemer T. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch. Toxicol. 66:1992;675-678.
14. Taylor K.M., Snyder S.H. Amphetamine: differentiation by D and L isomers of behavior involving brain norepinephrine or dopamine. Science. 168:1970;1487-1489.
15. Waitzinger J., Ludwig G., Pabst G., Michaelis K., Reh C. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). Int. J. Clin. Pharmacol. Ther. 34:1996;427-432.
16. 14C sulfate. J. Pharm. Sci. 54:1965;1586-1588.
17. Johnstone R.A.W., Payling D.W., Thomas C. A rapid method of N-alkylation of amines. J. Chem. Soc. C:1969;2223-2224.
18. Gan B.K., Baugh D., Liu R.H., Walia A.S. Simultaneous analysis of amphetamine, methamphetamine, and 3,4-methylenedioxymeliamphetamine (MDMA) in urine samples by solid-phase extraction, derivatization, and gas chromatography/mass spectrometry. J. Forensic Sci. 36:1991;1331-1341.
19. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokin. Biopharm. 6:1978;547-558.
20. Gunne L.M. The urinary output of D- and L-amphetamine in man. Biochem. Pharmacol. 16:1967;863-869.
21. Gal J. Stereochemistry of metabolism of amphetamines: use of (-)-α-methoxy-alpha-(trifluoromethyl)phenylacetyl chloride for GLC resolution of chiral amines. J. Pharm. Sci. 66:1977;169-172.
22. Liu J.H., Ku W.W. Determination of enantiomeric N-trifluoroacetyl-L-prolyl chloride amphetamine derivatives by capillary gas chromatography/mass spectrometry with chiral and achiral stationary phases. Anal. Chem. 53:1981;2180-2184.
23. Liu J.H., Ku W.W., Tsay J.T., Fitzgerald M.P., Kim S. Approaches to drug sample differentiation. III: A comparative study of the use of chiral and achiral capillary column gas chromatography/mass spectrometry for the determination of methamphetamine enantiomers and possible impurities. J. Forensic Sci. 27:1982;39-48.
24. Fitzgerald R.L., Ramos Jr J.M., Bogema S.C., Poklis A. Resolution of methamphetamine stereoisomers in urine drug testing: urinary excretion of R(-)-methamphetamine following use of nasal inhalers. J. Anal. Toxicol. 12:1988;255-259.
25. Hughes R.C., Bronner W.E., Smith M.L. Detection of amphetamine and methamphetamine in urine by gas chromatography/mass spectrometry following derivatization with (-)-menthyl chloroformate. J. Anal. Toxicol. 15:1991;256-259.
26. Mahmood I., Marinac J.S., Willsie S., Mason W.D. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm. Drug Disp. 16:1995;535-545.
27. Elsworth J.D., Sandler M., Lees A.J., Ward C., Stern G.M. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J. Neural. Transm. 54:1982;105-110.
28. Romberg R.W., Needleman S.B., Snyder J.J., Greedan A. Methamphetamine and amphetamine derived from the metabolism of selegiline. J. Forensic Sci. 40:1995;1100-1102.
29. Cody J.T., Schwarzhoff R. Interpretation of methamphetamine and amphetamine enantiomer data. J. Anal. Toxicol. 17:1993;321-326.
30. Hornbeck C.I., Czarny R.J. Retrospective analysis of some L-methamphetamine/L-amphetamine urine data. J. Anal. Toxicol. 17:1993;23-25.